# Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

> **NCT05429762** · PHASE1 · TERMINATED · sponsor: **Sanofi** · enrollment: 56 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** Tusamitamab ravtansine

## Key facts

- **NCT ID:** NCT05429762
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-03
- **Primary completion:** 2023-08-01
- **Final completion:** 2024-04-10
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern.
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429762, "Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05429762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*